GlaxoSmithKline’s (GSK) diabetes drug Avandia has such frightening side effects that the FDA will probably make it carry a "black box" label. Studies have found that the treatment can increase risk of heart attack.
Concerns about the side effect drove sales of the drug down 48% in the US during the September quarter.
Glaxo CEO Jean-Pierre Garnier told Reuters that sales might return if the "black box" warning is not too severe. "Absolutely. It all depends on what the language is," he said.
So, the FDA will have to tone down the part about heart attacks.
Douglas A. McIntyre
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
